Transgene S.A.
TRGNF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$189.21M
Close$
$0.03
96.1% downside
Current Fair Value
96.1% downsideOvervalued by 96.1% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $189.21 Million |
|---|---|
| Enterprise Value | $187.46 Million |
| Earnings per Share | $-0.26 |
| Beta | 0.72 |
| Outstanding Shares | 274,373,691 |
Return
| Return on Equity | -64.71% |
|---|---|
| Return on Assets | -56.74% |
| Return on Invested Capital | -60.84% |
Valuation & Multiples
| P/E Ratio | -4.07 |
|---|---|
| PEG | 20.95 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 271.35 |
| Enterprise Value to EBIT | -2.71 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Last Earnings Call
Report Date
September 24, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
March 31, 2027
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Transgene S.A.
156 employees
CEO: Alessandro Riva
Transgene SA is a biotechnology company focused on the research and development of therapeutic vaccines and oncolytic viruses, with a primary objective to treat cancer and infectious diseases. Its product pipeline includes TG4050, a ther...